Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non‐Familial Hypercholesterolemia

Progress in Cardiovascular Diseases

Volumn 59, Issue 2, 2016, Pages 165-171

  Robinson, Jennifer G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Ezetimibe; PCSK9 inhibitor; Risk reduction

Indexed keywords

ALIROCUMAB; CHOLESTEROL; COLESEVALAM; COLESTIPOL; COLESTYRAMINE; EVOLOCUMAB; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; GEMFIBROZIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; INJECTION SITE REACTION; METABOLIC SYNDROME X; MONOTHERAPY; MUSCLE DISEASE; NAUSEA; PATIENT PREFERENCE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOSIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VERY HIGH RISK PATIENT; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL DECISION MAKING; HYPERCHOLESTEROLEMIA; MEDICATION THERAPY MANAGEMENT;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL DECISION-MAKING; EZETIMIBE; HUMANS; HYPERCHOLESTEROLEMIA; MEDICATION THERAPY MANAGEMENT; PROPROTEIN CONVERTASE 9;

EID: 84992694478     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2016.07.011     Document Type: Review

References (45)

1. 1. Stone, NJ, Robinson, JG, Lichtenstein, AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: areport of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
2. 2. Cannon, CP, Blazing, MA, Giugliano, RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
3. 3. The ACCORD Study Group, Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
4. 4. The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropriprant in high-risk patients. N Engl J Med 371 (2014), 203–2012.
5. 5. The AIM-HIGH Investigators, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
6. 6. Sanofi Aventis and Regeneron Pharmaceuticals Inc, Praluent (Alirocumab Injection) manufacturer's Prescribing Information. 2015.
7. 7. Amgen, Repatha (Evolocumab) Injection Prescribing Information. 2015.
8. 8. Lipinski, MJ, Benedetto, U, Escarcega, RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 37 (2016), 536–545.
9. 9. Tice, JA, Kazi, DS, Pearson, SD, Proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for treatment of high cholesterol levels: effectiveness and value. JAMA Intern Med 176 (2016), 107–108.
10. 10. Joseph, L, Robinson, JG, Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Prog Cardiovasc Dis 58 (2015), 19–31.
11. 11. National Institute for Health and Care Excellence, Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease (Clinical Guideline 181). 2014.
12. 12. American Diabetes Association, 8. Cardiovascular disease and risk management. Diabetes Care 39 (2016), S60–S71.
13. 13. Institute of Medicine, Clinical Practice Guidelines we can Trust. 2011, National Academies Press, Washington DC.
14. 14. Piepoli, MF, Hoes, AW, Agewall, S, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 2016, 2016.
15. 15. Jacobson, TA, Ito, MK, Maki, KC, et al. National Lipid Association Recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol 9 (2015), 129–169.
16. 16. Grundy, SM, An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol 7 (2013), 561–565.
17. 17. Anderson, T, Gregoire, J, Hegele, R, et al. 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in teh adult. Can J Cardiol 29 (2012), 151–167.
18. 18. Stone, N, Robinson, J, Lichtenstein, A, Bairey Merz, C, Blum, C, Eckel, R, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 129 (2014), S1–45.
19. 19. Robinson, J, Stone, N, The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardivoascular disease risk: a new paradigm supported by more evidence. Eur Heart J 36 (2015), 2110–2118.
20. 20. Robinson, JG, Ray, K, Counterpoint: low-density lipoprotein cholesterol targets are not needed in lipid treatment guidelines. Arterioscler Thromb Vasc Biol 36 (2016), 586–590.
21. 21. Robinson, JG, Ray, K, Moving toward the next paradigm for cardiovascular prevention. Circulation, 2016 [online ahead of print April 20, 2016].
22. 22. Lloyd-Jones, DM, Morris, PB, Ballantyne, CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol 68:1 (2016), 92–125.
23. 23. Boekholdt, SM, Hovingh, GK, Mora, S, et al. Very low levels of Atherogenic lipoproteins and the risk for cardiovascular events: ameta-analysis of statin trials. J Am Coll Cardiol 64 (2014), 485–494.
24. 24. Puri, R, Nissen, SE, Libby, P, et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 128 (2013), 2395–2403.
25. 25. Robinson, J, Davidson, M, Combination therapy with ezetimibe and simvastatin to acheive aggressive LDL reduction. Expert Rev Cardiovasc Ther 4 (2006), 461–476.
26. 26. Amgen, Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER). [ClinicalTrials.gov Identifier: NCT01764633], 2014.
27. 27. Sanofi/Regeneron, ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes after an Acute Coronary Syndrome during Treatment with Alirocumab SAR236553 (REGN727). [ClinicalTrials.gov Identifier: NCT01663402], 2015.
28. 28. Steel, N, Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. Br Med J 320 (2000), 1446–1447.
29. 29. Robinson, J, Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. Vasc Health Risk Manag 5 (2009), 31–43.
30. 30. Rubins, H, Robins, S, Collins, D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 341 (1999), 410–418.
31. 31. The FIELD study investigators, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005), 1849–1861.
32. 32. Manninen, V, Elo, MO, Frick, MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki heart study. JAMA 260 (1988), 641–651.
33. 33. Robinson, JG, Smith, B, Maheshwari, N, Schrott, H, Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46 (2005), 1855–1862.
34. 34. Robinson, JG, Wang, S, Smith, BJ, Jacobson, TA, Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 53 (2009), 316–322.
35. 35. Ijioma, N, Robinson, J, Current and emerging therapies in hypercholesterolemia: focus on colesevelam. Clin Med Rev Vasc Health 2 (2010), 21–40.
36. 36. Lipid Research Clinics Program, The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984), 351–364.
37. 37. Jacobson, TA, Armani, A, McKenney, JM, Guyton, JR, Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 99 (2007), S47–S55.
38. 38. Davidson, MH, Armani, A, McKenney, JM, Jacobson, TA, Safety considerations with fibrate therapy. Am J Cardiol 99 (2007), S3–S18.
39. 39. Goff, DC Jr., Lloyd-Jones, DM, Bennett, G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: areport of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 63 (2014), 2935–2959.
40. 40. Robinson, JG, Heistad, DD, Fox, KAA, Atherosclerosis stabilization with PCSK-9 inhibition: an evolving concept for cardiovascular prevention. Atherosclerosis 243 (2015), 593–597.
41. 41. Shepherd, J, Barter, P, Carmena, R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets (TNT) study. Diabetes Care 29 (2006), 1220–1226.
42. 42. Holme, I, Fayyad, R, Faergeman, O, et al. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. J Intern Med 267 (2010), 567–575.
43. 43. Frey, P, Waters, DD, DeMicco, DA, et al. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the treating to new targets [TNT] and the incremental decrease in end points through aggressive lipid lowering [IDEAL] trials). Am J Cardiol 107 (2011), 145–150.
44. 44. Bangalore, S, Bhatt, DL, Steg, PG, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 7:6 (2014), 872–881.
45. 45. Stoekenbroek, RM, Boekholdt, SM, Fayyad, R, et al. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart 101 (2015), 356–362.